YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PhotoCure ASA (PHCUF) reported an 11% product revenu…
* Photocure ASA press release [https://seekingalpha.com/pr/20283591-photocure-asa-results-for-the-third-quarter-of-2025] (OTCPK:PHCUF [https://seekingalpha.com/symbol/PHCUF]): Q3 Revenue of NOK134.1M. * EBITDA of NOK 10.2 million MORE ON P…
* Photocure ASA press release [https://seekingalpha.com/pr/20182103-photocure-asa-results-for-the-second-quarter-of-2025] (OTCPK:PHCUF [https://seekingalpha.com/symbol/PHCUF]): Hexvix/Cysview revenues of NOK 135.6 million in the second qua…
OSLO, Norway, May 4, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET). The minutes (corrected) from the general meeting setting out the resolved resolutions are attached here…
OSLO, Norway, May 3, 2023 /PRNewswire/ -- Photocure ASA (Photocure) (PHO: OSE) will announce the first quarter 2023 financial results on Wednesday 10 May 2023 at 08:00 CEST and will present a live webcast at 14:00 CEST the same day. The qu…
OSLO, Norway, May 2, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that results from the Nordic Registry demonstrating benefits of Blue Light Cystoscopy (BLC®) were presented at the AUA 2023 Conferenc…
OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2022. The Board of Directors of Photocure ASA has approved the annual accounts for 2022. The fina…
OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 3 May 2023 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronex…
OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan,…
OSLO, Norway, Feb. 23, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 94.9 million in the fourth quarter of 2022 (Q4 2021: NOK 94.2 million), and an EBITDA of minus NOK 16.9 million (NOK -5.5…
OSLO, Norway, Feb. 20, 2023 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from the Veterans Affairs (VA) BRAVO study at the ASCO Genitourinary Cancers Symposium (ASCO GU) which was h…
OSLO, Norway, Jan. 3, 2023 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study 'Clinical and Economic Impact of Blue Light Cystoscopy in the Management of NMIBC* at U.S. Ambulatory Surgical Cen…
OSLO, Norway, Dec. 5, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at the 22nd Annual Society of Urologic Oncology (SUO) Meeting demonstrating that Blue Light Cystoscopy (BLC®) d…
OSLO, Norway, Nov. 7, 2022 /PRNewswire/ -- Photocure ASA., (OSE: PHO), announces that The United States Centers for Medicare & Medicaid Services (CMS) has released final payment rates in connection with the recently approved Medicare reimb…
OSLO, Norway, Nov. 2, 2022 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 96.9 million in the third quarter of 2022, up 12% compared to Q3 2021 (NOK 86.7 million), and positive EBITDA of NOK 4.7 mil…
OSLO, Norway, Oct. 4, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data and its breakout session in the scientific program at the International Bladder Cancer Network Meeting held S…
Karl Storz and Photocure to collaborate on commercializing the high-definition system OSLO, Norway, Sept. 28, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the commercial availability of Karl Storz's…
OSLO, Norway, Sept. 20, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the publication of first results from the Laser III clinical study in the medical journal, European Urology. The study is part of a systemati…
OSLO, Norway, Sept. 8, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, is delighted to continue supporting the global launch activities of the new and improved Blue Light Cystoscopy (BLC®) system to be used with Photocure's…
OSLO, Norway, Sept. 1, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Dr. Anders Neijber to the position of Chief Medical Officer, Global Medical Affairs and Clinical Developme…
OSLO, Norway, Aug. 10, 2022 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 99.9 million in the second quarter of 2022 (Q1 2021: NOK 88.9 million), and a positive EBITDA of NOK 1.4 million (NOK 5.8 m…
OSLO, Norway, Aug. 10, 2022 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 99.9 million in the second quarter of 2022 (Q1 2021: NOK 88.9 million), and a positive EBITDA of NOK 1.4 million (NOK 5.8 m…
OSLO, Norway, Aug. 9, 2022 /PRNewswire/ -- On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative drugs for the treatment of genitourinary tumors and other…
OSLO, Norway, Aug. 4, 2022 /PRNewswire/ -- Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2022 financial results on Wednesday 10 August 2022 at 08:00 CEST and invites investors, analysts and the me…
High-definition blue light cystoscopic imaging showcased at the European Association of Urology (EAU) Congress, Amsterdam OSLO, Norway, July 5, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces that its collaboratio…
Lower rates of bladder cancer recurrence and progression demonstrated in clinics with a high level of blue light cystoscopy (BLC®) use in primary patients Photocure sponsor of the Residents Day during the NUF congress OSLO, Norway, June 13…
OSLO, Norway, May 18, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the conclusion of a productive AUA 2022 Conference: the American Urological Association Annual Congress 2022, an in-person event for…
OSLO, Norway, May 11, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 81.4 million in the first quarter of 2022 (Q1 2021: NOK 81.6 million), following the recent Covid-19 surge and its impact o…
OSLO, Norway, March 29, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl will present corporate overviews…
OSLO, Norway, March 11, 2022 /PRNewswire/ -- Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (688176.SH) has obtained approval to conduct a real-world evidence study for Hexvix® in H…
OSLO, Norway, Feb. 28, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of new results from its exploratory research program in the journal Biomedicines, entitled "Antitumor Effect and In…
OSLO, Norway, Feb. 11, 2022 /PRNewswire/ -- Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has obtained the Phase III clinical trial application (CTA) approval from th…
OSLO, Norway, Feb. 8, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl will present a corporate overview a…
OSLO, Norway, Feb. 7, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces U.S. Food and Drug Administration (FDA) approval of a new and improved Blue Light system to be used with Photocure's Cysview® product in Blue L…
OSLO, Norway, Jan. 6, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that President and Chief Executive Of…
OSLO, Norway, Dec. 27, 2021 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner and exclusive distributor, Asieris MediTech in mainland China and Taiwan has communicated the first patient experi…